Abstract P165: MRTX1719: A first-in-class MTA-cooperative PRMT5 inhibitor that selectively elicits antitumor activity in MTAP/CDKN2A deleted cancer models
Smith, Christopher R., Engstrom, Lars D., Kulyk, Svitlana, Aranda, Ruth, Waters, Laura, Moya, Krystal, Bowcut, Victoria, Hebbert, Allan, Trinh, David, Briere, David M., Lawson, J. David, Clarine, Jeff, Rahbaek, Lisa, Christensen, James G., Marx, Matthew A., Olson, Peter
Published in Molecular cancer therapeutics (01.12.2021)
Published in Molecular cancer therapeutics (01.12.2021)
Get full text
Journal Article
The SOS1 Inhibitor MRTX0902 Blocks KRAS Activation and Demonstrates Antitumor Activity in Cancers Dependent on KRAS Nucleotide Loading
Sudhakar, Niranjan, Yan, Larry, Qiryaqos, Fadia, Engstrom, Lars D, Laguer, Jade, Calinisan, Andrew, Hebbert, Allan, Waters, Laura, Moya, Krystal, Bowcut, Vickie, Vegar, Laura, Ketcham, John M, Ivetac, Anthony, Smith, Christopher R, Lawson, J David, Rahbaek, Lisa, Clarine, Jeffrey, Nguyen, Natalie, Saechao, Barbara, Parker, Cody, Elliott, Adam J, Vanderpool, Darin, He, Leo, Hover, Laura D, Fernandez-Banet, Julio, Coma, Silvia, Pachter, Jonathan A, Hallin, Jill, Marx, Matthew A, Briere, David M, Christensen, James G, Olson, Peter, Haling, Jacob, Khare, Shilpi
Published in Molecular cancer therapeutics (21.06.2024)
Published in Molecular cancer therapeutics (21.06.2024)
Get full text
Journal Article
MRTX1719 Is an MTA-Cooperative PRMT5 Inhibitor That Exhibits Synthetic Lethality in Preclinical Models and Patients with MTAP-Deleted Cancer
Engstrom, Lars D, Aranda, Ruth, Waters, Laura, Moya, Krystal, Bowcut, Vickie, Vegar, Laura, Trinh, David, Hebbert, Allan, Smith, Christopher R, Kulyk, Svitlana, Lawson, J David, He, Leo, Hover, Laura D, Fernandez-Banet, Julio, Hallin, Jill, Vanderpool, Darin, Briere, David M, Blaj, Alice, Marx, Matthew A, Rodon, Jordi, Offin, Michael, Arbour, Kathryn C, Johnson, Melissa L, Kwiatkowski, David J, Jänne, Pasi A, Haddox, Candace L, Papadopoulos, Kyriakos P, Henry, Jason T, Leventakos, Konstantinos, Christensen, James G, Shazer, Ronald, Olson, Peter
Published in Cancer discovery (01.11.2023)
Published in Cancer discovery (01.11.2023)
Get full text
Journal Article
Abstract 7268: The SOS1 inhibitor MRTX0902 demonstrates activity across cancer models with mutations in proximal components of the RAS-MAPK pathway
Sudhakar, Niranjan, Yan, Larry, Qiryaqos, Fadia, Laguer, Jade, Briere, David, Hebbert, Allan, Calinisan, Andrew, Coma, Silvia, Pachter, Jonathan, Christensen, James G., Olson, Peter, Khare, Shilpi
Published in Cancer research (Chicago, Ill.) (22.03.2024)
Published in Cancer research (Chicago, Ill.) (22.03.2024)
Get full text
Journal Article
Abstract 3499: Inhibition of SOS1 by MRTX0902 augments the anti-tumor response of the targeted EGFR inhibitor osimertinib in NSCLC
Khare, Shilpi, Sudhakar, Niranjan, Laguer, Jade, Briere, David M., Yan, Larry, Hebbert, Allan, Calinisan, Andrew, Engstrom, Lars D., Qiryaqos, Fadia, Olson, Peter, Christensen, James G., Haling, Jacob R.
Published in Cancer research (Chicago, Ill.) (04.04.2023)
Published in Cancer research (Chicago, Ill.) (04.04.2023)
Get full text
Journal Article
Abstract 1943: Discovery and characterization of potential drivers of resistance to the KRAS G12D inhibitor, MRTX1133, in cancer cell line models
Helu, Xousaen M., Griffiths, Ellie, Calinisan, Andrew, Hebbert, Allan, Yan, Larry, Hoffman, Natalie, Trinh, David, Hover, Laura, Fernandez-Banet, Julio, Briere, David M., Lifset, Ella, Olson, Peter, Christensen, James G., Hallin, Jill
Published in Cancer research (Chicago, Ill.) (22.03.2024)
Published in Cancer research (Chicago, Ill.) (22.03.2024)
Get full text
Journal Article
Abstract 4448: Effects of adagrasib on cholesterol, lipid and glucose gene expression regulation in tumor xenograft models and patient samples
Shelton, Fabiola, Hoffman, Natalie, Trinh, David, Helu, Xousaen M., Calinisan, Andrew, Hebbert, Allan, Yan, Larry, Briere, David M., Hover, Laura, Fernandez-Benet, Julio, Anderes, Kenna, Christensen, James G., Hallin, Jill, Olson, Peter
Published in Cancer research (Chicago, Ill.) (22.03.2024)
Published in Cancer research (Chicago, Ill.) (22.03.2024)
Get full text
Journal Article
Abstract 3319: The MTA-cooperative PRMT5 inhibitor, MRTX1719, demonstrates increased anti-tumor activity in combination with KRAS mutant-selective inhibitors in MTAP del, KRAS -mutant cancers
Waters, Laura, Aranda, Ruth, Helu, Xousaen, Vegar, Laura, Moya, Krystal, Calinisan, Andrew, Hebbert, Allan, Hallin, Jill, Vanderpool, Darin, Briere, David M., Christensen, James G., Olson, Peter A., Engstrom, Lars D.
Published in Cancer research (Chicago, Ill.) (22.03.2024)
Published in Cancer research (Chicago, Ill.) (22.03.2024)
Get full text
Journal Article
Abstract 2779: Identification of mechanism-based combination targets effective with the MTA-cooperative PRMT5 inhibitor MRTX1719 for the treatment of MTAP deleted cancers
Waters, Laura, Aranda, Ruth, Moya, Krystal, Bowcut, Victoria, Trinh, David, Hebbert, Allan, He, Leo, Hover, Laura D., Fernandez-Banet, Julio, Hallin, Jill, Briere, David M., Christensen, James G., Olson, Peter A., Engstrom, Lars D.
Published in Cancer research (Chicago, Ill.) (04.04.2023)
Published in Cancer research (Chicago, Ill.) (04.04.2023)
Get full text
Journal Article
Abstract 2778: A novel MTA-cooperative PRMT5 inhibitor, MRTX1719, stabilizes the ternary MTA-PRMT5 complex and leads to synthetic lethality in MTAP deleted cancers
Vegar, Laura, Aranda, Ruth, Waters, Laura, Moya, Krystal, Hebbert, Allan, Smith, Christopher S., Hallin, Jill, David, Briere M., Engstrom, Lars D., Vanderpool, Darin, Marx, Matthew M., Christensen, James G., Olson, Peter A.
Published in Cancer research (Chicago, Ill.) (04.04.2023)
Published in Cancer research (Chicago, Ill.) (04.04.2023)
Get full text
Journal Article